1. Introduction {#s0005}
===============

A novel coronavirus disease-2019 (COVID-19) outbreak was reported in Wuhan, Hubei province, P.R.C, in December 2019, and quickly spread to all provinces and municipalities nationwide in China, even spread around the world. The pathogen is a novel coronavirus (SARS-COV-2) which was never found by humans before has been named as COVID-19 by the World Health Organization officially in February 2020 ([@bb0125]). SARS-COV-2 also targets the respiratory tract and shares multiple similar clinical symptoms with MERS-COV and SARS-COV ([@bb0110]). The most common symptoms of COVID-19 involved fatigue, fever and dry cough, followed always by myalgia, anorexia, dyspnea, and so on ([@bb0005]). There were more than 5.1 million cases of COVID-19 diagnosed in the whole world, and more than 332,000 people had died by May 22, 2020. At present, there are already 10 countries in the world with a cumulative number of more than 100,000 diagnosed cases ([@bb0120]). Among them, the United States is still the country with the largest number of diagnoses in the world, with a cumulative total of 1,618,000 confirmed cases. Therefore, following Middle East respiratory syndrome coronavirus (MERS-COV) and severe acute respiratory syndrome coronavirus (SARS-COV), and SARS-COV-2 has been the third coronavirus that causes infections worldwide in the past 20 years. A public health threat was made by outbreak of COVID-19, and overall countries are allocating scientific and medical resources to fight the COVID-19 pandemic ([@bb0180]).

As the most widely investigated erythrocyte antigen system and straightforward accessible element in an individual\'s genetic makeup ([@bb0135]), ABO blood group system is used in clinical practice extensively ([@bb0165]; [@bb0025]). After ABO blood group system was found by Karl Landsteiner in 1901, we never interrupted searching for the relationship between ABO blood group system and various diseases ([@bb0105]). It has been suggested that ABO blood group system is related to many bacterial ([@bb0010]) and virus infection, such as helicobacter pylori ([@bb0015]), norovirus ([@bb0115]), HBV ([@bb0095]), SARS-COV ([@bb0070]) and MERS-COV ([@bb0155]). Recently, several studies about COVID-19 in China and America discovered relationships between ABO blood group and COVI9--19 infection, severity and demise ([@bb0185]; [@bb0190]). However, there are some contradictions in the results of the studies. [@bb0185] found that COVID-19 infection was higher in AB blood group, but [@bb0190] found that AB blood group was related with decreased COVID-19 infection. Moreover, [@bb0185] found A blood group links to higher mortality of COVID-19, O blood group links to lower mortality; [@bb0180] has not yet find any association between blood type and COVID-19 mortality. The contradiction from included studies could due to small sample size, residual con-founding from population heterogeneity, region difference etc.

In present study, we performed a review with meta-analysis comprehensive and summarized literature systematically on the relationship of ABO blood group with COVID-19 infection, severity and demise. The objective of this was therefore to prevent COVID-19 infection, and provide more vigilant surveillance and aggressive treatment to susceptible blood type, which can assist in accomplishing the target of eliminating COVID-19 as a cosmopolitan public health challenge.

2. Methods {#s0010}
==========

2.1. Database and search strategy {#s0015}
---------------------------------

A systematic and comprehensively online search for published literature was carried out in PubMed, MedRxiv, BioRxiv, Web of Science and CNKI with the MESH (medical subject heading) terms "ABO blood group" and "COVID-19". In order to expand our search scale, we also conducted a full-text search with search terms "COVID-19", "blood group" and "ABO". The time for the searching article to be published were limited between November 1st 2019 to April 20th 2020, and there was no limitation of region. We identified studies and did screening, selection and data extraction manually.

2.2. Study selection {#s0020}
--------------------

Inclusion criteria were as fulfilled: 1) a clear extractable typing of ABO blood type; 2) studies contain impersonal diagnosed COVID-19+ and normal individuals; 3) studies contain severe and mild patients infected with COVID-19; 4) studies contain dead and alive patients infected with COVID-19; 5) studies providing original data. After removing duplicates, articles\' titles and abstracts were screened and whole contents of qualified articles critiqued by two authors independently with the inclusion criteria.

2.3. Data extraction {#s0025}
--------------------

Four authors reached a consensus on all items. We chose a data collection standard to extract the following information: 1) the first author; 2) publication year; 3) country of the participants; 4)study design; 5)sample size; 6)gender ratio; 7)symptomatic cases and asymptomatic controls; 8)severe cases and non-severe controls; 9) died cases and live controls. When there was a controversy over a study, all reviewer intervened to determine whether the study can be included or not.

2.4. Methodological quality assessment of the included studies {#s0030}
--------------------------------------------------------------

The quality of studies was adapted to assess based on the Newcastle--Ottawa Scale (NOS) ([@bb0030]). All included studies were rated based on three main domains, including selection, comparability and exposure. The supreme score for each dimensions was 4 points, 2 points and 3 points, respectively ([@bb0140]). Therefore, we classified studies as poor quality if they scored 0--3 points, fair quality if they scored within the range of 4-5points, if they scored within the range of 6--8 points or 9--10 points, we think them as high-quality studies or excellent-quality studies.

2.5. Statistical analysis {#s0035}
-------------------------

Statistical analysis for included studies were carried out using Stata. Pooled odds ratios (ORs) and 95% confidence interval (CIs) were obtained using either fix-effects model or random-effects model to measure the association between the ABO blood group and infection, severity, and mortality of COVID-19. A random-effects model was applied when there was high heterogeneity (Moran\'s I^2^ ≥ 30% or *P* ≤ 0.05), likewise, the fixed-effects model was applied (Moran\'s I^2^ \< 30% or *P* \> 0.05) ([@bb0045]; [@bb0080]). Besides, Egger\'s regression test and Begg\'s adjusted rank correlation test were used to evaluated publication bias (bias if *P* \< 0.1) ([@bb0085]; [@bb0075]). Meanwhile, we used sensitivity analysis to examine robustness of the overall summary effects ([@bb0050]).

3. Results {#s0040}
==========

3.1. Overall outcomes {#s0045}
---------------------

The search resulted in a total of 186 studies from 5 databases: PubMed (*n* = 87), MedRxiv (*n* = 12), BioRxiv (*n* = 4), Web of Science (*n* = 12) and CNKI (*n* = 71). With 111 studies subsequently removed because they were duplicates. Following the inclusion criteria, we excluded the 69 irrelevant studies by screening abstract and title. Finally, a total of 4 articles that included in quantitative synthesis were included in this systematic review and meta-analysis. The details of the methodological quality and classification of the studies are showed in [Fig. 1](#f0005){ref-type="fig"} .Fig. 1Flow diagram showing selection of studies.Fig. 1

3.2. Characteristics of the included studies {#s0050}
--------------------------------------------

We identified 4 ([@bb0180]; [@bb0185]; [@bb0190]; [@bb0175]) studies that met our inclusion criteria for meta-analysis. Selected characteristics of the study participants are shown in [Table 1](#t0005){ref-type="table"} . All studies were published in 2020, and 3 in China, 1 in the United States. Of all the studies, 2 were considered in high quality(scored ≥7), 2 were considered in mediate quality (score 6 points). In first study, distributions of ABO blood groups from Shenzhen (cases from Shenzhen Third People\'s Hospital, controls from Shenzhen general population) and Wuhan (cases from Wuhan Jinyintan Hospital and Renmin Hospital of Wuhan University, controls from Wuhan general population). The second study, attributing to the insufficient number of patients that individuals of AB blood group were not statistically analyzed. In third study, distributions from New York City data, which from the CUIMC EHR/NYP system. In forth study, distributions of blood groups from the First Affiliated Hospital of Nanchang University.Table 1Characteristic of included studies.Table 1StudyCountryStudy designSampleAgeGender (M/F)Symptomatic casesAsymptomatic controlsSevere casesNon-severe controlsDied casesAlive controlsNOS[@bb0180]ChinaRetrospective234\>13133/101009713721766[@bb0185]ChinaRetrospective5469NRNR177536940020615698[@bb0185]ChinaRetrospective3807NRNR113369400008[@bb0185]ChinaRetrospective23,671NRNR28523,38600008[@bb0190]ColumbiaRetrospective1559NR716/843682877179423806028[@bb0175]ChinaRetrospective5418--7833/1600549006[^1][^2][^3]

3.3. Associations between ABO blood group and COVID-19 infection {#s0055}
----------------------------------------------------------------

Results of the relationship between ABO blood type and infection of COVID-19 were recorded in [Table 2](#t0010){ref-type="table"} . In blood group A and blood group non-A (OR: 1.249, 95%CI: 1.114--1.440, *P* \< 0.001), the meta-analysis in [Fig. 2](#f0010){ref-type="fig"} showed that people with blood type A were related to an increased risk of COVID-19 infection compared to non-A blood group. Besides, people with blood type O were related to a decreased risk of COVID-19 infection compared to non-O blood type (OR: 0.699, 95%CI: 0.635--0.770, *P* \< 0.001). The random-effects model was applied to above two analyses. Studies with blood type B and non-B were analyzed with no statistical significance ((I^2^ = 0, *P* = 0.593) using a fixed-effects model. Studies with blood type AB and non-AB were analyzed also with no statistical significance (I^2^ = 83.6%, *P* = 0) using a random-effects model.Table 2Results of the infection analysis.Table 2First author, YearCOVID-19+COVID-19-COVID-19+COVID-19-COVID-19+COVID-19-COVID-19+COVID-19-ANon-AANon-ABNon-BBNon-BABNon-ABABNon-ABONon-OONon-OJiao Zhao, [@bb0185]6701105118825064691306920277417815973363358458131712502444Jiao Zhao, [@bb0185]4568118825062588920277415983363358288512502444Jiao Zhao, [@bb0185]82203672816,65883202588017,50639246171221,67481200906614,320Michael Zietz, [@bb0190]2334492456321165661367412166147830312370449428Fig. 2Meta-analysis forest of the infection of ABO blood groups for COVID-19.Fig. 2

[Fig. 3](#f0015){ref-type="fig"} shows the publication bias. The Egger\'s test and Begg\'s test suggested no significant publication bias among individuals with blood type A and non-A, blood type B and non---B, blood type AB and non-AB, blood type O and non---O. Begg\'s test for asymmetry *P* = 0.810, 0.764, 0.997, and 0.923, respectively. Egger\'s test for asymmetry *P* = 1.000, 0.937, 1.000 and 1.000, separately. Sensitivity analyses in [Fig. 4](#f0020){ref-type="fig"} shows the pooled estimated did not transform too much, it means the results of meta-analysis were robust.Fig. 3Publication bias of the infection of ABO blood groups for COVID-19.Fig. 3Fig. 4Sensitively analyzes of the infection of ABO blood groups for COVID-19.Fig. 4

3.4. Associations between ABO blood group and COVID-19 severity {#s0060}
---------------------------------------------------------------

Results of the relationship between ABO blood type and severity of COVID-19 were shown in [Table 3](#t0015){ref-type="table"} . We used random-effects models on following 4 studies. The meta-analysis in [Fig. 5](#f0025){ref-type="fig"} showed that individuals with blood group AB were related to an increased risk of severe COVID-19 compared to blood group non-AB with an OR of 2.424 (95%CI: 0.934--6.294, *P* = 0.069). Meanwhile, compared to other ABO blood groups, individuals with A blood group (OR: 1.055, 95%CI: 0.783--1.422, *P* = 0.723) and B blood group (OR: 1.271, 95%CI: 0.894--1.806, *P* = 0.181) seemed to have a trend of higher risk for severity. On the other hand, result of individuals with blood group O showed a reduced risk of severe COVID-19 compared with non-O (OR: 0.748, 95CI%: 0.556--1.077, *P* = 0.056). Overall, the four results are lack of statistical significance.Table 3Results of the severity analysis.Table 3First author, YearSevereNon-severeSevereNon-severeSevereNon-severeSevereNon-severeANon-AANon-ABNon-BBNon-BABNon-ABABNon-ABONon-OONon-OXianfei Zeng, [@bb0180]40575483306734103097013727704988Michael Zietz [@bb0190]6211714427935144693548171841574105202221Xiang Tianxin, [@bb0175]32192114103005139141030Fig. 5Meta-analysis forest of the severity of ABO blood groups for COVID-19.Fig. 5

Publication bias of four groups that used Begg\'s test. Blood group A vs group non-A (*P* = 0.296), blood group B vs group non-B (*P* = 1.000), blood group AB vs group non-AB (*P* = 1.000) and blood group O vs group non-O (*P* = 1.000), thus there was no prominent publication bias. What\'s more, we also conducted sensitivity analysis on them, and we found no substantial alteration to the results after moving whichever study and re-analyzing the data sets.

3.5. Associations between ABO blood group and COVID-19 demise {#s0065}
-------------------------------------------------------------

[Fig. 6](#f0030){ref-type="fig"} shows the estimates of ORs of the associations between ABO blood group and COVID-19 demise on the pooled data from our studies by random effects models. Similarly, compared with individuals with blood group O and blood group B, individuals with blood group A and blood group AB were associated with an increased the risk of death (for group A, OR: 1.124, 95%CI: 0.879--1.124, *P* = 0.352; for group AB, OR: 1.348, 95%CI: 0.507--1.348, *P* = 0.549). However, individuals with blood group B (OR: 0.891, 95%CI: 0.669--1.422, *P* = 0.433) and blood group O (OR: 0.972, 95%CI: 0.746--1.265, *P* = 0.831) seemed to have a higher mortality rate. Above all, the meta-analysis attach to no statistical significance ([Table 4](#t0020){ref-type="table"} ).Fig. 6Meta-analysis forest of the mortality of ABO blood groups.Fig. 6Table 4Results of the demise analysis.Table 4First author, YearYearDiedAliveDiedAliveDiedAliveDiedAliveANon-AANon-ABNon-BBNon-BABNon-ABABNon-ABONon-OONon-OXianfei Zeng, [@bb0180]2020813274971423530210766152155Jiao Zhao, [@bb0185]202085121585984501564191150191871591410521544061163Michael Zietz, [@bb0190]202027532063961268104498575165963644276326

It suggested no asymmetry in the exploration for the plots of blood types in demise of COVID-19, and Begg\'s test didn\'t provide proof for publication bias among individuals with blood group A and non-A(*P* = 1.000), blood group B and non-B (*P* = 1.000), blood group AB and non-AB (*P* = 1.000), blood group O and non-O (*P* = 0.296). Next, we did the sensitively analyzes of four sets of data. After omitting the study by any of them, the pooled ORs did not alter much that the results of analysis were likely to robust.

4. Discussion {#s0070}
=============

In current study, we found that individuals with blood type A link a higher risk of infecting COVID-19 (OR: 1.249, 95%CI: 1.114--1.400), whereas individuals with blood type O link a lower risk to COVID-19 infection (OR: 0.699, 95%CI: 0.635--0.770). Above findings have highly statistically significance. Besides, the odds of COVID-19 severity were higher in individuals with blood group AB (OR: 2.424, 95%CI: 0.934--6.294), and lower in individuals with blood group O (OR: 0.748, 95%CI: 0.556--1.007); blood group AB were at increased risk of COVID-19 demise (OR: 1.348, 95%CI: 0.507--3.583), while blood group B were at decreased risk of it (OR: 0.891, 95%CI: 0.669--1.188).

The results we carried out were incomplete consistent to other analytical studies. According to [@bb0185], individuals with blood group A might be more susceptible to infect COVID-19 and have a higher mortality than non-A blood group, while those with blood group O might have a protective effect. The feasible explanation for inconsistence is the difference between individuals of the same blood type from different races and regions. In study by [@bb0190] it showed a decreased risk of COVID-19 infection among individuals with blood type O, what\'s more, it also suggested that significant association only between A+ (blood type A and Rh+) and O+ (blood type O and Rh+) after further stratifying by Rh. Given the number of Rh blood groups are fewer in our samples, we didn\'t conduct further analyses, so this issue needs further research and discussion. In other study by [@bb0180] found the odds of COVID-19 infection was higher in individuals with A blood group, but they were unable to find O blood group could be protective against COVID-19 infection, instead, their study showed blood group O were at lower risk of severe COVID-19., it was probably due to the sample size.

Though the mechanism of ABO blood type in COVID-19 infection has yet to elucidate, we still propose the following conjectures based on conclusions drawn by predecessors. ABO blood group is specific antigen type on erythrocyte membrane, but blood group antigens is expressed in airway epithelial cells, alveolar epithelial cells and even in body fluids [@bb0145]. Firstly, we supposed through binding receptor-mediated affinity, genetic susceptibility of blood group glycoproteins can function, particularly invasion mechanism. And the study by Cooling has proved blood group antigens are valid receptors for some infections microorganisms ([@bb0025]; [@bb0130]). Given our knowledge of the SARS virus, the adhesion of SARS-COV S protein-expressing cells could be inhibited specifically by anti-A antibodies ([@bb0070]; [@bb0020]), simultaneously, SARS-COV and SARS-COV-2 have similar nucleic acid sequence and similar receptor combination with angiotensin-converting enzyme 2 (ACE2) ([@bb0160]; [@bb0060]; [@bb0170]). Thus, we suspect that anti-A antibodies will play a similar role in COVID-19. Secondly, Koike C et al. suggested that anti-A and/or anti-B antibodies may neutralize the virus to effectively protect body when polymorphic blood group antigens expressed on the surfaces of red blood cells and epithelia are utilized as attachment receptors by HIV ([@bb0100]), perhaps for COVID-19, anti-A antibodies and/or anti-B antibodies also have the effect of neutralizing the SARS-COV-2. Thirdly, when combined anti-A or anti-B with cells of schistosome, it was suggested the unique ABO blood group antigen could confer appropriate specificity upon them ([@bb0055]; [@bb0035]; [@bb0065]), which was regarded as one of the interpretations why O type blood is not prone to schistosomiasis ([@bb0150]). Finally, it has been suggested that blood group O could prevent severe *Plasmodium falciparum* malaria through the mechanism of reducing rosettes ([@bb0090]; [@bb0040]), so we speculated that blood type O has a similar effect on SARS-COV-2.

The potential clinical implications of current study deserve mention. Our study shed light on blood group A is more susceptible to COVID-19, and blood group O is less susceptible to it, which could provide supportive evidence that studying the association between ABO blood group and COVID-19 infection. Meanwhile, our finding suggests that individuals with blood group A are supposed to do better personal protection to minimize the possibility of infection. Moreover, we discussed in depth the association between ABO blood group and severity，demise of COVID-19, which may contribute to the victory over SARA-CoV-2.

The potential limitations of our study need to be considered. First of all, despite we had the large number of samples, the source of them were not diverse. Our samples lack cases from Europe and Africa. Due to the serious epidemic situation, we were unable to collect data and make on the spot investigation in Europe and Africa. Second, since the short medical resources were used for emergency treatment of a large number of patients, we didn\'t collect prospective cohorts to determine when healthy patients infect COVID-19.

5. Conclusions {#s0075}
==============

In conclusion, the current analyses validated individuals with blood type A are related to a higher risk and individuals with blood type O are related to a lower risk to infect SARS-COV-2, and there were no significant relationships between ABO blood group and of COVID-19 severity and demise. The interest of this study assists people realize the relationship between ABO blood group and infection, severity and demise of COVID-19. Moreover, further investigations and studies are recommended to clarify the present finding and provide more beneficial insights into COVID-19.
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